Xvivo Perfusion AB (publ) Stock price

Equities

XVIVO

SE0004840718

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 11:29:57 2023-11-28 am EST Intraday chart for Xvivo Perfusion AB (publ) 5-day change 1st Jan Change
262.00 SEK -0.95% +1.95% +43.17%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Sales 2023 * 613 M 59.04 M Sales 2024 * 867 M 83.54 M Capitalization 8,332 M 803 M
Net income 2023 * 37.00 M 3.57 M Net income 2024 * 119 M 11.47 M EV / Sales 2023 *
12,7x
Net cash position 2023 * 559 M 53.85 M Net cash position 2024 * 514 M 49.57 M EV / Sales 2024 *
9,02x
P/E ratio 2023 *
218x
P/E ratio 2024 *
65,0x
Employees 144
Yield 2023 *
-
Yield 2024 *
-
Free-Float 74.50%
More Fundamentals * Assessed data
Dynamic Chart
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published CI
Transcript : Xvivo Perfusion AB, Q3 2023 Earnings Call, Oct 24, 2023 CI
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial CI
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee CI
Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue MT
Xvivo Perfusion Gets USFDA Nod on Using Donated Hearts in Heart Preservation Clinical Trial MT
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial CI
Xvivo Perfusion Closes PrimECC Trial Amid Patient Recruitment Challenges MT
Transcript : Xvivo Perfusion AB, Q2 2023 Earnings Call, Jul 13, 2023 CI
Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Xvivo Perfusion AB Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated CI
XVIVO Perfusion AB Enters into A Strategic Collaboration with MTJ Aviation to Strengthen Organ Procurement Services in the US CI
Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology CI
Patient Inclusion Completed in European Clinical Trial with XVIVO's Heart Preservation Technology CI
More news
1 day-0.95%
1 week+1.95%
Current month+12.93%
1 month+14.16%
3 months-6.76%
6 months-6.93%
Current year+43.17%
More quotes
1 week
257.00
Extreme 257
272.50
1 month
221.50
Extreme 221.5
272.50
Current year
182.40
Extreme 182.4
335.00
1 year
171.60
Extreme 171.6
335.00
3 years
127.80
Extreme 127.8
459.00
5 years
70.30
Extreme 70.3
459.00
10 years
29.80
Extreme 29.8
459.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 2012
Director of Finance/CFO 38 -
Chief Tech/Sci/R&D Officer 56 2020
Members of the board TitleAgeSince
Director/Board Member 59 2016
Chairman 64 -
Director/Board Member 68 2019
More insiders
Date Price Change Volume
23-11-28 262.00 -0.95% 26 387
23-11-27 264.50 0.00% 81,434
23-11-24 264.50 +1.54% 12,152
23-11-23 260.50 -2.07% 12,891
23-11-22 266.00 +3.50% 21,412

Delayed Quote Nasdaq Stockholm, November 28, 2023 at 11:29 am EST

More quotes
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company's product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
264.50SEK
Average target price
391.67SEK
Spread / Average Target
+48.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Xvivo Perfusion AB (publ) - Nasdaq Stockholm
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer